Abstract
The impairment of regulatory T cells (Tregs) is a characteristic feature of autoimmune hepatitis (AIH), and the degradation of tryptophan (Trp) to kynurenine (Kyn), by gamma interferon-induced indoleamine-2,3-dioxygenase-1 (IDO-1), is a central metabolomics check point in the differentiation of Tregs. For this reason, we investigate whether or not Kyn and IDO activity is potentially useful biomarkers in pediatric AIH.
Between January 2016 and January 2017, children of AIH type-1 (AIH-1, n = 37), AIH type-2 with liver kidney microsome-1 autoantibodies (AIH-2-LKM-1, n = 8), and autoantibody-negative Wilsons Disease (WD, n = 8) and alpha-1 anti-trypsin deficiency (AATD, n = 10), were enrolled in a cross-sectional survey of Kyn and Trp levels and Kyn/Trp ratios (IDO activity) by HPLC, and neopterin levels by ELISA.
The mean Kyn and mean Kyn/Trp ratios of AIH-1 with smooth muscle antigen (SMA) 1.85 μM and 27 μmole/mmole, and AIH-2-LKM-1; 1.7 μM and 28.6 μmole/mmole were lower than that of the WD; 2.2 μM p = 0.03 and 33 μmole/mmole p = 0.02 and of AATD; 2.3 μM, p = 0.02 and 55 μM, p = 0.001. Kyn/Trp ratios of AIH relapse; 23.6 μmole/mmole were lower than Kyn/Trp ratios of AIH remission; 27.6 μmole/mmole (p < 0.05). The stage of liver disease and grade of liver biopsies in AIH-1 patients negatively correlated with the Kyn/Trp ratios.
The serum Kyn levels and Kyn/Trp ratio of AIH patients, within or below the normal range, indicate a trend of IDO activity lower than non-autoimmune WD or AATD. Prospective monitoring of serum tryptophan metabolomics in larger cohorts of pediatric AIH patients is required to confirm the apparent paradigm of weak IDO activity contributing to the Treg deficit and pathogenesis of pediatric AIH.
Similar content being viewed by others
Abbreviations
- AIH-1:
-
type 1 autoimmune hepatitis
- AIH-2:
-
type II autoimmune hepatitis
- ALT:
-
alanine aminotransferase
- IDO:
-
indoleamine-2,3-dioxygenase-1
- Tregs:
-
T-regulatory cells
- IFNγ:
-
interferon gamma
- IFA:
-
immune fluorescence assay
- ANA:
-
anti-nuclear antigen
- AST:
-
aspartate aminotransferase
- AZA:
-
azathioprine
- GGTP:
-
gamma-glutamyltranspeptidase
- LC1:
-
anti-liver cytosol antigen 1
- LKM-1:
-
anti-liver kidney microsome 1
- SMA:
-
anti-smooth muscle antigen
- AATD:
-
anti-alpha trypsin deficiency
- WD:
-
Wilsons Disease
- Kyn:
-
kynurenine
- Trp:
-
tryptophan
References
Doherty DG. Immunity, tolerance and autoimmunity in the liver: a comprehensive review. J Autoimmun. 2018;66:60–75.
Wawman RE, Bartlett H, Oo YH. Regulatory T cell metabolism in the hepatic microenvironment. Front Immunol. 2018;8:1889. https://doi.org/10.3389/fimmu.2017.01889.
Grant CR, Holder BS, Liberal R, Heneghan MA, Ma Y, Mieli-Vergani G, et al. Immunosuppressive drugs affect interferon (IFN)-γ and programmed cell death 1 (PD-1) kinetics in patients with newly diagnosed autoimmune hepatitis. Clin Exp Immunol. 2017;189:71–82.
Behairy BE, El-Araby HA, Abd El Kader HH, et al. Assessment of intrahepatic regulatory T cells in children with autoimmune hepatitis. Ann Hepatol. 2016;15:682–90.
Xue Y, Michalopoulos G. Tregs: a therapeutic target for the treatment of portal fibrosis? Dig Dis Sci. 2015;60:1878–80.
Alvarez F, Berg PA, Bianchi FP. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929e938.
Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193–213.
Hennes EM, Zeniya M, Czaja AI, Pares A, Dalekos GN, et al. International autoimmune hepatitis group simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169–76.
EASL Clinical Practice Guidelines. Autoimmune hepatitis European association for the study of the liver. J Hepatol. 2015;63:971–1004.
Mieli-Vergani G, Vergani D, Baumann U, Czubkowski P, Debray D, Dezsofi A, et al. Diagnosis and management of paediatric autoimmune liver disease: ESPGHAN hepatology committee position statement. J Pediatr Gastroenterol Nutr. 2017;66(2):345–60.
Floreani A, Liberal R, Vergani D, Mieli-Vergani G. Autoimmune hepatitis: contrast and comparison in children and adults-a comprehensive review. J Autoimmun. 2013;46:7–16.
Healey R, Corless L, Gordin P, Holding S. Do anti-smooth muscle antibodies predict development of autoimmune hepatitis in patients with normal liver function? A retrospective cohort review. Autoimmun Rev. 2016;15:668–72.
Liberal R, Vergani D, Mieli-Vergani G. Update on autoimmune hepatitis. J Clin Trans Hepatol. 2015;3:42–52.
Woynarowski M, Woźniak M, Cukrowska B, Cukrowska B, Wierzbicka A, Lytton SD. Autoantibody profile of adult patients with childhood onset type 2 autoimmune hepatitis. J Clin Lab Anal. 2016;30(5):590–6.
Duchini A, McHutchison JG, Pockros PJ. LKM-positive autoimmune hepatitis in the western United States: a case series. Am J Gastroenterol. 2000;95:3238–41.
Gregorio GV, Portmann B, Reid F, Donaldson PT, Doherty DG, McCartney M, et al. Autoimmune hepatitis in childhood: a 20-year experience. Paedatic J Clin Transl Hepatol. 2015;42–52(43):3.
Gatselis NK, Zachou K, Koukoulis GK, Dalekos GN. Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics. World J Gastroenterol. 2015;21:60–83.
Bogdanos DP, Invernizzi P, Mackay IR, Vergani D. Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol. 2008;14:3374–87.
Villata D, Girolami E, Alessio MG, et al. Autoantibody profiling in a cohort of pediatric and adult patients with autoimmune hepatitis. J Clin Lab Anal. 2016;30:41–6.
Paolo M, Cumali E, Luigi M, Ersan O Schiano T, Yoshida EM, Heurgué-Berlot, et al. Clinical implications of antimitochondrial antibody seropositivity in autoimmune hepatitis: a multicentre study. Eur J Gastroenterol Hepatol. 2017;29:777–80.
Roggenbruck D, Mytilnaiou MG, Lapin SV, Rheinhold D, Conrad K. Asialoglycoprotein receptor (ASGPR): a peculiar target of liver-specific autoimmunity. Autoimmun Highlights. 2012;3:119–25.
Norman GL, Yang CY, Ostendorff HP, Lim MJ, Wang J, et al. Anti-Kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis. Liver Int. 2015;35:642–51.
Lytton SD, Berg U, Nemeth A, Ingelman-Sundberg M. Autoantibodies against cytochrome P450s in sera of children treated with immunosuppressive drugs. Clin Exp Immunol. 2012;127:293–302.
Woynarowski M, Nemeth A, Baruch Y. Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents. J Pediatr. 2013;163:1347–53.
Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol. 1995;19:1409–17.
Goodman GD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol. 2007;47:598–607.
Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson Disease: an update. Hepatology. 2008;47:2090–111.
Lauletta G, Russi S, Pavone F, Marzullo A, Tampoia A, Sansonno D, et al. Autoimmune hepatitis: factors involved in initiation and methods of diagnosis and treatment. Crit Rev Immunol. 2016;36:407.428.
Dhaliwal HK, Hoeroldt BS, Dube AK, McFarlane E, Underwood JC, Karajeh MA, et al. Long-term prognostic significance of persisting histological activity despite biochemical remission in autoimmune hepatitis. Am J Gastroenterol. 2015;110:993–9.
Aizawaa Y, Abea H, Sugitaa T, Sekia N, Chuganjic Y, Furumotoc Y, et al. Centrilobular zonal necrosis as a hallmark of a distinctive subtype of autoimmune hepatitis. Eur J Gastroenterol Hepatol. 2016;28:391–7.
Abdel-Razik A, Mousa N, Zakaria S, Elhelaly R, Elzehery R, Zalata K, et al. New predictive factors of poor response to therapy in autoimmune hepatitis: role of mean platelet volume. Eur J Gastroenterol Hepatol. 2017;29:1373–9.
Diestelhorst J, Junge N, Jonigk D, Schlue J, Falk CS, Manns MP, et al. Baseline IL-2 and the AIH score can predict the response to standard therapy in paediatric autoimmune hepatitis. Sci Rep. 2018;8:419.
Dounay AB, Tuttle JB, Verhoest PR. Challenges and opportunities in the discovery of new therapeutics targeting the kynurenine pathway. J Med Chem. 2015;58:8762–82.
Zuo H, Ueland PM, Ulvik A, Eussen S, et al. Plasma biomarkers of inflammation, the kynurenine pathway, and risks of all-cause, cancer, and cardiovascular disease mortality: the Hordaland health study. Am J Epidemiol. 2016;183:249–58.
Lippens C, Duraes FV, Dubrot J, Brighouse D, Lacroix M, Irla M, et al. IDO-orchestrated crosstalk between pDCs and Tregs inhibits autoimmunity. J Autoimmun. 2016;75:39–49.
Mancuso R, Hernis A, Agostini S, Rovaris M, Caputo D, Fuchs D, et al. Indoleamine 2,3 dioxygenase (IDO) expression and activity in relapsing-remitting multiple sclerosis. PlosOne. 2015;10:e0130715. https://doi.org/10.1371/journal.pone.0130715.
Llamas-Velasco M, Bonay P, José Concha-Garzón M, Corvo-Villén L, Cibrián D, Sanguino-Pascual A, et al. Immune cells from patients with psoriasis are defective in inducing indoleamine 2,3-dioxygenase expression in response to inflammatory stimuli. Br J Dermatol. 2017;176:695–704.
Bernard NJ. Rheumatoid arthritis: who knows why regulatory T cells are defective in RA. IDO Nat Rev Rheumatol. 2014;10:381–96.
Konstantia-Maria C, Shukla D, Keteepe-Arachi T, Sekel JA, Fuchs D, Pussey CD, et al. Regulation of myeloperoxidase-specific T cell responses during disease remission in anti-neutrophil cytoplasmic antibody–associated vasculitis: the role of Treg cells and tryptophan degradation. Arthritis Rheum. 2010;62:1539–48.
Palabiyik SS, Keles S, Girgin G, Arpali-Tanas E, Topdagi E, Baydar T. Neopterin release and tryptophan degradation in patients with uveitis. Curr Eye Res. 2016;41:1513–7.
Kaden J, Abendroth DE, Völp M, Marzinzig M, Wesslau C. Causes and prognostic value of pre-transplant elevated kynurenine level in kidney allograft recipients. Ann Transplant. 2014;19:51–9.
Kaden J, Abendroth D, Völp A, Marzinzig M. Dynamics and diagnostic relevance of kynurenine serum level after kidney transplantation. Ann Transpl. 2015;20:327–37.
Yoshio S, Sugiyama M, Shoji H, et al. Indoleamine-2,3-dioxygenase as an effector and an indicator of protective immune responses in patients with acute hepatitis B. Hepatol. 2016;63:3–94.
Jenabian MA, Patel M, Kema I, Kanagaratham C, Radzioch D, Thébault P, et al. Distinct tryptophan catabolism and Th17/Treg balance in HIV progressors and elite controllers. PLoS One. 2013;8:e78146. https://doi.org/10.1371/journal.pone.0078146.
Bipath P, Levay PF, Viljoen M. The kynurenine pathway activities in a sub-Saharan HIV/AIDS population. BMC Infect Dis. 2015;15:346–61.
Mehraj J, Routy JP. Tryptophan catabolism in chronic viral infections: handling uninvited guests. Int J Tryptophan Res. 2015;8:41–6.
Zoller H, Jenal A, Staettermayer AF, Schroecksnadel S, Ferenci P, Fuchs D. Tryptophan breakdown in patients with HCV infection is influenced by IL28B polymorphism. Pharmaceuticals. 2015;8:337–50.
Danikowski KM, Jayaraman S, Prabhaka BS. Regulatory T cells in multiple sclerosis and myasthenia gravis. J Neuroinflammation. 2017;14:117–33.
Geisler S, Mayersbach P, Becker K, Schennach H, Fuchs D, Gostner JM. Serum tryptophan, kynurenine, phenylalanine, tyrosine and neopterin concentrations in 100 healthy blood donors. Pteridines. 2015;26:31–6.
Schröcksnadel K, Wirleitner B, Winkler C, Fuchs D. Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta. 2016;364:82–90.
Gibson RN, Donlan JD, Ditchfield MR, Bhathal PS. Duplex Doppler ultrasound of the ligamentum teres and portal vein: a clinically useful adjunct in the evaluation of patients with known or suspected chronic liver disease or portal hypertension. J Gastroenterol Hepatol. 1991;6:61–5.
Acknowledgements
We thank all the patients who kindly consented to participate in this study and the cooperation of nursing staff for the collection and storage of serum.
Financial support
The research expenses were incurred in part by SeraDiaLogistics and EB Group Sp. All material support is identified in the acknowledgements section.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by Ethics Committee of the Children’s Memorial Health Institute no 192/KBE/2015 and 231/KBE/2015.
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Lytton, S.D., Osiecki, M., MałgorzataWoźniak et al. Tryptophan-kynurenine profile in pediatric autoimmune hepatitis. Immunol Res 67, 39–47 (2019). https://doi.org/10.1007/s12026-019-9068-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12026-019-9068-1